Vertex refines terms on $300M public offering

Vertex Pharmaceuticals has priced a public offering of 9.1 million shares at $33, hoping to raise slightly more than $300 million in the process. The new terms include an additional 1.1 million shares above what the company had revealed just four days ago at a slightly trimmed share price. Vertex makes the HIV drugs Agenerase and Lexiva and has other drugs for cancer and hepatitis C in its pipeline.

- here's the AP report on Vertex

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.